2nd Next Generation Ophthalmic Drug Delivery Summit

The 2nd Annual Next Generation Ophthalmic Drug Delivery Summit is returning to San Francisco this January to unite 90+ device engineers, biochemists, preclinical and clinical experts as they discuss how they are optimizing longer-lasting and less invasive delivery to the back of the eye to reduce patient concerns and burden on healthcare systems caused by frequent drug administration.

Join 23+ expert speakers from the likes of AbbVie, Boehringer Ingelheim, Bayer, Genentech, Janssen, Novartis, and Clearside Biomedical at the only industry-dedicated event focusing on overcoming key translational challenges of developing and implementing novel delivery technology as they progress their ophthalmic pipelines to the clinic.

URLs:
Website: https://go.evvnt.com/2005017-0?pid=10018
Tickets: https://go.evvnt.com/2005017-2?pid=10018
Brochure: https://go.evvnt.com/2005017-3?pid=10018

Prices:
Drug Developer Pricing - Conference + Workshop Day: USD 4946.00,
Drug Developer Pricing - Conference Only: USD 2999.00,
Solution Provider Pricing - Conference + Workshop Day: USD 6046.00,
Solution Provider Pricing - Conference Only: USD 3799.00

Speakers: Annahita Keravala, Founder, Exhaura, Arun Upadhyay, Chief Scientific Officer and Head of Research, Development and Medical, Ocugen, Ashwath Jayagopal, Chief Scientific Officer, Opus Genetics, Cameron Lee, Associate Director, Novartis, Emily Ross, Technical Development Scientist, Genentech, Fabio Baschiera, Global Clinical Leader Ophthalmology, Bayer, Hemant Khanna Vice President, Preclinical Ocular Research, Iveric Bio, Jie Shen, Vice President, Senior Research Fellow, Translational Sciences, AbbVie, Justin Creel, Head of Targeted Therapeutics Delivery Center, Novartis, Marshall Huston, Associate Director, Gene Therapy, Janssen, Max Cotler, Chief Operating Officer, GelMEDIX, Moshe Weinstein, Chief Executive Officer, Everads Therapy, Nicolas Lonfat, Senior Research Scientist II, Iveric Bio, Paulina Jakubiak, Senior Scientist, Genentech, Quan Dong Nguyen, Professor of Ophthalmology, Medicine, and Pediatrics, Stanford Medicine, Riad Sherif, Chief Executive Officer, Oculis, Ronald Yamamoto, Chief Scientific Officer, Oxular, Sammy Bell, Senior Director, External Alternative Drug Product Development, Boehringer Ingelheim, Scott Edwards, Chief Development Operations Officer, OcuTerra, Stephen Poor, Global Program Clinical Head, Novartis, Subrata Batabyal, Senior Technical Officer, Nanoscope Therapeutics, Susie Crowell, Senior Principal Scientist, Genentech, Viral Kansara, Vice President, Preclinical Development, Clearside Biomedical